

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Adenoma, hepatic, 449
 - metanephric, 492–493, 494
- Adrenal carcinoma, differential diagnosis of, 504–505
- Adrenal hemorrhage, differential diagnosis of, 505–506, 508
- Adrenal neuroblastic tumors, differential diagnosis of, 504–506, 507, 508
- Adrenal pheochromocytoma, 504, 507
- Alagille syndrome, 459–461
- Angiomyolipoma, 489–491
- Angiosarcoma, 442
- Annular pancreas, 458–459
- Appendicitis, MR imaging in, 476–477
- Arteries, great, transposition of, 423, 426
- Artifacts, impacting musculoskeletal imaging at 3 T, 535–537
 - magnetic resonance, on cardiac MR imaging, 404
 - motion, reduction of, in MR imaging, 395–399
 - MR cholangiopancreatography and, 456–457
- Atrial septal defects, MR imaging of, 413, 415–417

B

- Balanced steady-state imaging, 392, 393, 395–396
- Beckwith-Wiedmann syndrome, 484
- Biliary anomalies, congenital, 459–463
- Biliary atresia, 459, 460
- Biliary calculi, 464
- Biliary tree, development of, 457, 458
 - normal anatomy and variants of, 457–458
- Bladder, catheterization of, for MR urography, 516
- Blalock-Taussig shunt, for tetralogy of Fallot, 428, 429
- Botryoid Wilms' tumor, 482, 484
- Bowel, inflammatory disease of. See *Inflammatory bowel disease*.
 - MR imaging of, clinical indications for, 470–477
 - pediatric applications of, **467–478**
 - small, transplantation of, MR imaging of, 477
 - vascular malformations of, MR imaging of, 477
- Bowel scan, for imaging in inflammatory bowel disease, 468–469, 471
- Breathhold scanning T1-weighted imaging, 390, 394

C

- Carcinoma, adrenal, differential diagnosis of, 504–505
 - hepatocellular, 439–441, 442

- Cardiac MR imaging, cardiac gating in, 404, 407
 - magnetic resonance artifact on, 404
 - patient preparation/monitoring for, 404–407
 - scanning protocol for, 404, 405, 408–413
 - standard examination for, 411
 - techniques of, 403–413
- Caroli syndrome, 460, 461–462
- Cartilage, evaluation of, gradient echo imaging for, 542, 543
- Cholangiopancreatography, MR, advanced techniques for: 3 T MR imaging, 454–455
 - artifacts and, 456–457
 - contrast agents for, 454
 - diagnosis at, pitfalls in, 455–456
 - patient preparation for, 454
 - techniques of, 453–457
 - and applications of, **453–466**
 - for imaging pancreaticobiliary system, 453–454
- Choledochal cysts, 461, 462
- Choledochoceles, 461, 462
- Cholelithiasis, 462
- Clear cell sarcoma, 488, 490
- Coarctation of aorta, 418, 422–423
- Computed tomography, multidetector, 403
- Contrast-enhanced dynamic imaging, 389, 392–393
- Crohn's disease, early stage, MR enterography in, 470–471, 472, 473, 474, 475–476
 - oral contrast administration for, 468, 469
- Cysts, hepatic, 449–450
 - rectal duplication, 511

D

- Diffusion weighted imaging, 396, 397, 399

E

- Ebstein's anomaly, MR imaging of, 416, 421

F

- Fibrolamellar hepatocellular carcinoma, 439–441, 442
- Fistula, perianal, MR enterography in, 471, 475
- Focal masses, in pediatric liver, **437–452**
- Focal nodular hyperplasia, 448–449
 - treatment of, 449
- Fontan shunt, for tricuspid atresia, 428, 429
- Furosemide, for MR urography, 516

G

- Gadolinium contrast, in musculoskeletal imaging at 3 T, 540
- Ganglioneuroblastoma, 504
- Ganglioneuroma, 504, 507
- Glenn shunt, for tricuspid atresia, 428, 429
- Gradient echo imaging, for cartilage evaluation, 542, 543
- Great vessels, levo-transposition of, 424, 427–428

H

- Hamartoma, mesenchymal, 446–448
- Hemangioendothelioma, MR imaging appearance of, 444–445, 446
 - treatment of, 445–446
- Hemangioma, hepatic, 444
 - MR imaging appearance of, 444–445, 446
 - treatment of, 446
- Hemihypertrophy, idiopathic, 484
- Hemorrhage, adrenal, differential diagnosis of, 505–506, 508
- Hepatic adenoma, 449
- Hepatic cysts, 449–450
- Hepatic fibrosis, congenital, 461–462
- Hepatic metastases, 443
- Hepatic MR imaging techniques, coils for, 437
 - imaging sequences in, 437
 - technical factors in, 438
- Hepatic tumors, evaluation of, 438
 - imaging strategies for, 438
 - technical factors in, 438
- Hepatoblastoma, 438–439
 - MR imaging appearance of, 439, 440, 441, 442
 - treatment of, 439
- Hepatocellular carcinoma, 439
 - fibrolamellar, 439–441, 442
 - MR imaging appearance of, 439, 441
 - treatment of, 439
- Hydronephrosis, classification of obstruction in, 523, 524
 - clinical features and physiology of, 522–523
 - MR evaluation of, 523–525
 - MR urography in, 522
- Hyperpolarized gas and carbon imaging, 397, 398, 399
- Hypoplastic left heart syndrome, 425, 428

I

- Image postprocessing, 411, 413–415
 - flow quantification in, 415
 - of ventricular function, 411, 415
- Imaging systems, 3.0 Tesla (3.0 T), artifacts
 - associated with, chemical shift and, 388–389
 - standing waves and, 389

- T2* effects with, 387–388
 - coils for, 386
 - energy deposition at, 387
 - for musculoskeletal imaging. See *Musculoskeletal MR imaging at 3 T.*
 - minimizing absorption of energy in, 387
 - pulse sequences for, 386–387
 - transition to, 385–389

- Inflammatory bowel disease, imaging in,
 - antiperistaltic drug administration for, 468
 - bowel scan for, 468–469, 471
 - MR enterography findings in, 470–471, 472, 473, 474, 4750
 - MR enterography versus conventional and CT enteroclysis in, 472–476
 - MR enterography versus ileocolonoscopy in, 472–476
 - MR enterography versus MR enteroclysis in, 471–472
 - oral contrast administration for, 468, 469
 - patient preparation for, 468
 - pelvic scan for, 469–470
 - rectal contrast administration for, 468, 470
 - technique of, 467–470
- Intestinal polyps, MR imaging of, 477

J

- Jatene arterial switch operation, 431, 433

K

- Kidneys, congenital malformations of, 528–529

L

- Leukemia, 489
- Lipomeningocele, 511
- Liver, angiomatous lesions of, 443–446
 - benign neoplasms of, 443–449
 - epithelial lesions of, 448–449
 - malignant tumors metastasizing to, 443
 - normal, MR imaging of, 438
 - pediatric, focal masses in, **437–452**
 - primary malignant neoplasms of, 438–442
 - regenerative nodules of, 449, 450
- Lymphangioma, 446–448
- Lymphoma, 489, 492
- Lymphoproliferative disorder, posttransplant, 443

M

- Mediastinal masses, posterior, differential diagnosis of, 506–508, 509
- Medullary carcinoma, renal, 488–489, 491
- Mesenchymal hamartoma, 446–448

- Mesoblastic nephroma, 491–492, 493
- Metanephric adenoma, 492–493, 494
- MR cholangiopancreatography. See *Cholangiopancreatography, MR.*
- MR enterography, in inflammatory bowel disease, 470–471, 472, 473, 474, 475
- MR imaging, 3.0 Tesla (3.0 T). See *Imaging systems, 3.0 Tesla (3.0 T).*
- cardiac. See *Cardiac MR imaging.*
- in appendicitis, 476–477
- in congenital heart disease, 415–428
- practical applications of, **403–435**
- motion artifact reduction in, 395–399
- of bowel, clinical indications for, 470–477
- pediatric applications of, **467–478**
- of Wilms' tumor. See *Wilms' tumor, MR imaging of.*
- parallel imaging in. See *Parallel imaging.*
- pediatric, advances in, **385–402**
- MR imaging at 3 T, musculoskeletal. See *Musculoskeletal MR imaging at 3 T.*
- MR imaging techniques, hepatic. See *Hepatic MR imaging techniques.*
- MR urography, in children. See *Urography, MR, in children.*
- Multidetector CT, 403
- Musculoskeletal imaging, and pediatric body imaging, future of, 395, 398–399
- Musculoskeletal MR imaging at 3 T, **533–545**
- advantages of, 533–534
- and 1.5 T, for knee examination, 539, 541
- artifacts impacting, 535–537
- challenges of, 534
- clinical applications of, 541–543
- energy deposition-specific absorption rate, 534–535
- gadolinium contrast in, 540
- parallel imaging in, 540–541
- protocols and image optimization in, 541
- signal-to-noise ratio of, absorption rate of, 534–535
- methods of optimizing, 534
- tissue contrast and, 537, 538–540
- Mustard and Senning procedures, 431, 432
- Myelomeningocele, 511
- N**
- Navigation imaging, 397
- Nephroblastoma. See *Wilms' tumor.*
- Nephroblastomatosis, 485–486, 488
- Nephrogenic rests, 485–486
- Nephroma, mesoblastic, 491–492, 493
- Nephropathy, reflux, 525–527
- Neuroblastic masses, MR imaging of, **499–513**
- Neuroblastic tumors, adrenal, differential diagnosis of, 504–506, 507, 508
- Neuroblastoma, 499–504
- clinical findings in, 499–500
- diagnostic imaging in, 501–503
- distant spread of, MR characteristics of, 502–503, 506, 507
- genetics of, 499
- imaging techniques in, compared, 503
- local spread of, MR characteristics of, 502
- pathology of, 500
- posttreatment evaluation in, 504
- primary, MR imaging of, 501–502, 503, 504
- prognostic features of, 500
- staging of, 500, 501
- treatment and outcome of, 500–501
- with bone marrow metastases, 502–503, 507
- Neuroectodermal tumor, primitive, 488, 491
- O**
- Opsoclonus-myoclonus syndrome, 500
- P**
- Pancreas, agenesis or hypoplasia, 459
- annular, 458–459
- congenital anomalies of, 458–459
- development of, 457, 458
- inflammatory diseases of, 462
- normal anatomy and variants of, 457–458
- trauma to, 463–464
- Pancreas divisum, 458–459
- Pancreaticobiliary neoplasms, 464, 465
- Pancreaticobiliary system, MR
- cholangiopancreatography for imaging, 453–454
- Pancreatitis, 462–463
- Parallel imaging, applications in children, 392–395
- artifact reduction with, 390, 394
- basic methods of, 388, 389–392
- in volumetric (three dimensional) T2-weighted techniques, 390, 391, 394–395
- to increase imaging speed, 389
- Patent ductus arteriosus, MR imaging of, 415, 419, 425
- Pediatric body imaging, and musculoskeletal imaging, future of, 395, 398–399
- Pediatric MR imaging, advances in, **385–402**
- Pelvic scan, for imaging in inflammatory bowel disease, 469–470
- Perianal fistula, MR enterography in, 471, 475
- Pheochromocytoma, adrenal, 504, 507
- Polyyps, intestinal, MR imaging of, 477
- Posttransplant lymphoproliferative disorder, 443
- Potts shunt, for tricuspid atresia, 430, 431
- Presacral masses, differential diagnosis of, 508–511
- PROPELLER imaging, 397–398
- Pseudocoarctation of aorta, 419, 423

Pseudotruncus arteriosus, MR imaging of, 421, 425
 Pulmonary atresia, 421
 Pulmonary venous return, partial/total anomalous, 419, 423

R

Rastelli procedure, 430, 431
 Real-time imaging, 394, 396–397
 Rectal duplication cysts, 511
 Reflux nephropathy, 525–527
 Renal cell carcinoma, 486, 488
 Renal dysplasia, 527, 528
 Renal masses, pediatric, Wilms' tumor and, **479–497**
 Renal medullary carcinoma, 488–489, 491
 Renal obstruction, classification of severity of, 525
 Renal tumor(s), benign, 489–494
 multilocular cystic, 493, 494
 ossifying, of infancy, 492
 Rhabdoid tumor, 486–488
 Ross procedure, 431, 432

S

Sacrococcygeal teratoma, differential diagnosis of, 508–511
 Sclerosing cholangitis, primary, 462–463
 Septal patch, failure of, 426, 429
 Shunt lesions, MR imaging of, 415–419
 Signal-to-noise ratio, higher, 386
 in musculoskeletal MR imaging at 3 T, 534–535

T

Tetralogy of Fallot, MR imaging of, 420, 424–425
 3.0 Tesla (3.0 T) imaging systems. *See Imaging systems, 3.0 Tesla (3.0 T).*
 Transesophageal echocardiography, 403
 Transthoracic echocardiography, 403
 Tricuspid atresia, MR imaging of, 416, 420–421
 Truncus arteriosus, MR imaging of, 422, 425–426

U

Ultrahigh field strength imaging, 395, 398–399
 Undifferentiated (embryonal) sarcoma, 441–442, 443
 Urography, MR, **515–531**
 bladder catheterization for, 516
 clinical applications of, 522–525
 excretory, calyceal transit times for, 520
 contrast administration for, 516–517
 differential renal function in, 520
 dynamic contrast-enhanced sequence for, 517, 518, 519

 high spatial resolution imaging for, 517–518, 521
 processing in, 518–522
 renal transit time for, 519–520
 signal intensity versus time curves in, 520–522
 furosemide for, 516
 hydration for, 515
 in hydronephrosis, 522
 in obstructive uropathy, 522
 patient preparation for, 515–516
 sedation for, 515–516
 static-fluid, 516
 techniques of, 516
 obstructive, 522, 525
 Uropathy, obstructive, MR urography in, 522

V

Valve prosthesis, leak of, 427, 429
 Valvular regurgitation, 417, 422
 Valvular stenosis, due to bicuspid aortic valve, 417, 421–422
 Ventricular septal defects, MR imaging in, 414, 418
 Volumetric (three dimensional) T2-weighted techniques, 390, 391, 394–395

W

Waterston-Cooley shunt, for tetralogy of Fallot, 430
 Wilms' tumor, and other pediatric renal masses, **479–497**
 botryoid, 482, 484
 clinical findings in, 481
 comparative imaging in, 484
 distant disease extent in, evaluation of, 483, 486, 487
 epidemiology of, 480
 follow-up imaging in, 484
 high-risk patients for, screening of, 483–484
 histology and biologic behavior in, 481
 local disease extent in, evaluation of, 482–483, 486, 487
 MR imaging of, 482
 contrast-enhanced imaging in, 480
 imaging parameters for, 479
 imaging sequences for, 479–480
 optimizing image quality in, 480
 pulse sequences for, 479–480
 technique of, 479–480
 pelvic extrarenal, 454, 482
 primary, imaging features of, 482–484, 485
 risk factors for, 480–481
 staging in, 481–482